Back to search results

T2 Star MRI and Blood Tests for Malignant Gliomas

This study is looking at whether a special type of MRI called T2 star (T2*) magnetic resonance imaging and blood tests can help predict how malignant gliomas (a type of brain tumor) might change or grow over time. Researchers want to see if these tests can help identify if the tumor is coming back after treatment. You would undergo T2* MRI, standard MRI, and give blood samples. To join, you need to be over 21, have a new diagnosis of a specific type of malignant glioma (WHO grade IV), have a KPS score over 60 (a measure of your ability to perform daily activities), and be able to give informed consent for standard treatments and study procedures. The main goal is to see how T2* MRI relates to a specific marker in your blood up to three months after radiation therapy. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 15 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo T2* MRI, standard MRI, and provide blood samples. The primary endpoint is measured up to 3 months post-radiation therapy.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured up to 3 months post-radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07447531

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Recruiting
NAAges 21+InterventionalDiagnostic
John M. Buatti
~15 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:T2 (Observed)-Weighted ImagingBiospecimen CollectionMagnetic Resonance Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relationship between T2 (observed)-weighted imaging (T2*) magnetic resonance imaging relation time and dimeric transferrin receptor expression
Measured over Up to 3 months post-radiation therapy

Conditions

Malignant Glioma

Explore related trials

Malignant Glioma

Where it's being run

1 sites across 1 states
Iowa1

Study leadership

  • John Buatti, MD · PRINCIPAL_INVESTIGATOR · University of Iowa

Who to contact

John Buatti, MD
[email protected]
(319) 356-7590
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 21 years
New pathologically confirmed diagnosis of WHO grade IV malignant glioma
KPS \> 60
Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion

History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
History of iron metabolic disorder such as hemochromatosis
Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

What this trial measures

  • Relationship between T2 (observed)-weighted imaging (T2*) magnetic resonance imaging relation time and dimeric transferrin receptor expressionUp to 3 months post-radiation therapy

    Will be characterized with mixed effects regression modeling. Correlation between the two biomarkers will be estimated with the multivariate linear mixed effects regression approach of Hamlett, Ryan, and Wolfinger. Cluster bootstrapping will be employed to calculate a 95% confidence interval for their correlation and a p-value for testing its significance at the 5% level.